ArticleiScience2026

Antigen-directed single domain antibody-based TNFR1 agonists elicit preferential killing of HER2-overexpressing cancer cells.

Laura Unmuth et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.